keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/27915962/generalized-pustular-psoriasis-von-zumbusch-type-following-renal-transplant-a-case-report
#1
Georgia Dedemadi, Maria Koukoulaki, Vassileios Vougas, Constantinos Noutsis, Aikaterini Pantelidaki, Spiros Drakopoulos
Generalized pustular psoriasis appears as an uncommon variant form of psoriasis consisting of widespread pustules on an erythematous background (von Zumbusch). A 39-year-old male patient with a history of plaque psoriasis since the age of 9 who had an acute relapse of generalized pustular psoriasis 12 days following a successful renal transplantation is presented. Despite administered immunosuppression for transplantation, the addition of cyclosporine and methotrexate did not reverse the ongoing process of disease and the patient died on the 57th posttransplant day due to multiorgan failure subsequent to severe bone marrow suppression...
December 2, 2016: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/27908543/from-the-medical-board-of-the-national-psoriasis-foundation-treatment-targets-for-plaque-psoriasis
#2
April W Armstrong, Michael P Siegel, Jerry Bagel, Erin E Boh, Megan Buell, Kevin D Cooper, Kristina Callis Duffin, Lawrence F Eichenfield, Amit Garg, Joel M Gelfand, Alice B Gottlieb, John Y M Koo, Neil J Korman, Gerald G Krueger, Mark G Lebwohl, Craig L Leonardi, Arthur M Mandelin, M Alan Menter, Joseph F Merola, David M Pariser, Ronald B Prussick, Caitriona Ryan, Kara N Shah, Jeffrey M Weinberg, MaryJane O U Williams, Jashin J Wu, Paul S Yamauchi, Abby S Van Voorhees
BACKGROUND: An urgent need exists in the United States to establish treatment goals in psoriasis. OBJECTIVE: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice. METHODS: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds...
November 22, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27904275/hidden-pictures-of-kaposi-s-sarcoma-in-psoriatic-lesions-a-diagnostic-challenge
#3
Jisook Yoo, Mingyul Jo, Min-Soo Kim, Kwang-Hyun Choi, Hyang-Joon Park, Mihn-Sook Jue
Kaposi's sarcoma is a multifocal proliferative vascular tumor involving the skin and other organ and psoriasis is a chronic cutaneous disease with papules and plaques with white scale. Development of Kaposi's sarcoma in psoriasis patients has been reported rarely. A 71-year-old man presented with multiple brownish to violaceous plaques on both feet and arms which were found 4 months ago. The biopsy confirmed Kaposi's sarcoma. The patient was diagnosed with psoriasis vulgaris 10 years ago and Kaposi's sarcoma lesions developed between psoriatic plaques...
December 2016: Annals of Dermatology
https://www.readbyqxmd.com/read/27900946/childhood-psoriasis
#4
Emmanuel Mahé
Psoriasis is a common chronic inflammatory skin disease. Recently, few data have been published on epidemiology, comorbidity, or therapy in children with psoriasis. Psoriasis affects up to 2% of children in Europe, even during the first months of life. The link between psoriasis and metabolic comorbidities has been highlighted, notably in relation to excessive weight and obesity. The clinical picture of psoriasis in childhood resembles adult disease, however, some clinical features are noteworthy: neonatal diaper rash is relatively specific, face involvement and guttate psoriasis are more common, plaques are often smaller, and scales are finer and softer than in adults...
November 29, 2016: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/27892456/il-12-protects-from-psoriasiform-skin-inflammation
#5
Paulina Kulig, Stephanie Musiol, Sandra Nicole Freiberger, Bettina Schreiner, Gabor Gyülveszi, Giancarlo Russo, Stanislav Pantelyushin, Kenji Kishihara, Francesca Alessandrini, Thomas Kündig, Federica Sallusto, Günther F L Hofbauer, Stefan Haak, Burkhard Becher
Neutralization of the common p40-subunit of IL-12/23 in psoriasis patients has led to a breakthrough in the management of moderate to severe disease. Aside from neutralizing IL-23, which is thought to be responsible for the curative effect, anti-p40 therapy also interferes with IL-12 signalling and type 1 immunity. Here we dissect the individual contribution of these two cytokines to the formation of psoriatic lesions and understand the effect of therapeutic co-targeting of IL-12 and IL-23 in psoriasis. Using a preclinical model for psoriatic plaque formation we show that IL-12, in contrast to IL-23, has a regulatory function by restraining the invasion of an IL-17-committed γδT (γδT17) cell subset...
November 28, 2016: Nature Communications
https://www.readbyqxmd.com/read/27891342/immunohistochemical-evaluation-of-role-of-serotonin-in-pathogenesis-of-psoriasis
#6
Sheren Fouad Younes, Ola Ahmed Bakry
INTRODUCTION: Psoriasis is a common skin disorder characterized by erythaematosquamous papules and plaques. It is known to be associated with stressful and depressive disorders. Serotonin is a neurotransmitter that plays a role in the pathogenesis of inflammatory skin disorders. AIM: To evaluate the role of serotonin in pathogenesis of psoriasis. MATERIALS AND METHODS: Using standard immunohistochemical techniques, 24 biopsies from patients with chronic plaque psoriasis were examined together with 12 biopsies from age and gender-matched healthy subjects as a control group...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27887675/clinical-efficacy-and-safety-of-ixekizumab-for-treatment-of-psoriasis
#7
A Azevedo, T Torres
Psoriasis is a common, chronic, inflammatory skin disorder with a physical and emotional burden. Emerging evidence suggests that IL17-A is a key cytokine in the immunopathogenesis of psoriasis. Ixekizumab is a humanized IgG4 monoclonal antibody that acts by neutralizing IL-17A. Data from Phase I-III studies reveal that ixekizumab is highly effective in treating patients with moderate-to-severe plaque psoriasis. A large proportion of patients receiving ixekizumab achieved or maintained complete or near complete resolution of psoriatic lesions with an acceptable safety profile through week 60...
November 22, 2016: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/27885324/clinical-outcome-of-a-novel-anti-cd6-biologic-itolizumab-in-patients-of-psoriasis-with-comorbid-conditions
#8
Vinay Singh
Psoriasis is a common, chronic, immune mediated, inflammatory disease of skin characterized by red patches enclosed with white scales and affects 2-3% of people in the world. Topical therapy, phototherapy, and systemic therapy were employed for management of disease from many last decades. However, long term uses of these agents are associated with unwanted effects and toxicities. Recently, Itolizumab has been developed as world's first anti-CD6 humanized monoclonal IgG1 antibody for the management of moderate-to-severe chronic plaque psoriasis in India...
2016: Dermatology Research and Practice
https://www.readbyqxmd.com/read/27882586/efficacy-and-safety-of-dose-escalation-of-infliximab-therapy-in-japanese-patients-with-psoriasis-results-of-the-spread-study
#9
Hideshi Torii, Masayuki Nakano, Toshiro Yano, Kazuoki Kondo, Hidemi Nakagawa
Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard-dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75...
November 24, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27881939/can-pregnancy-associated-plasma-protein-a-be-a-marker-for-the-assessment-of-atherosclerosis-risk-in-patients-with-chronic-plaque-psoriasis
#10
Mualla Polat, Guler Bugdayci, Asli Sahin, Hatice Kaya, Tuna Sezer, Serkan Ozturk
INTRODUCTION: Psoriasis is an immune-mediated chronic inflammatory dermatosis. Several studies have shown that patients with psoriasis have a much greater risk of cardiovascular diseases than the normal population. The chronic inflammation observed in psoriasis is thought to have a role in the development of atherosclerosis and vascular endothelial injury. AIM: To examine serum pregnancy-associated plasma protein-A (PAPP-A) levels, which has been regarded as a marker of early stage atherosclerosis in patients with psoriasis that do not have concurrent conventional cardiovascular risk markers...
October 2016: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/27878061/oral-apremilast-for-the-treatment-of-plaque-psoriasis
#11
REVIEW
James Q Del Rosso, Leon Kircik
This article provides an update on the use of oral apremilast, a phosphodiesterase-4 (PDE4) inhibitor, for the treatment of plaque psoriasis. Emphasis is placed on safety evaluations, although efficacy considerations are also addressed. Both two-year and three -year data analyses support the favorable safety profile reported in pivotal trials with this agent. Although effective in many study subjects despite baseline characteristics, higher response rates were noted in those with a baseline psoriasis area and severity index (PASI) score <20 and in subjects not previously treated with systemic therapy for psoriasis...
September 2016: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/27876460/imo-8400-a-toll-like-receptor-7-8-and-9-antagonist-demonstrates-clinical-activity-in-a-phase-2a-randomized-placebo-controlled-trial-in-patients-with-moderate-to-severe-plaque-psoriasis
#12
Deepak M W Balak, Martijn B A van Doorn, Robert D Arbeit, Rianne Rijneveld, Erica Klaassen, Tim Sullivan, Julie Brevard, H Bing Thio, Errol P Prens, J Koos Burggraaf, Robert Rissmann
BACKGROUND: Aberrant toll-like receptors (TLRs) 7, 8, and 9 activation by self-nucleic acids is implicated in immune-mediated inflammatory diseases (IMIDs) such as psoriasis. In preclinical IMID models, blocking TLR-activation reduced disease severity. IMO-8400 is a first-in-class, oligonucleotide-based antagonist of TLRs 7, 8, and 9. We evaluated the short-term safety and proof-of-concept for efficacy of IMO-8400 in a first-in-patient phase 2 trial. METHODS: Forty-six psoriasis patients were randomly assigned to IMO-8400 in four dose levels or placebo for 12weeks...
November 19, 2016: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/27869356/apremilast-an-oral-phosphodiesterase-4-pde4-inhibitor-a-novel-treatment-option-for-nurse-practitioners-treating-patients-with-psoriatic-disease
#13
Melodie Young, Heather L Roebuck
BACKGROUND AND PURPOSE: Apremilast is an oral nonbiologic medication approved for the treatment of adult patients with active psoriatic arthritis and for patients with moderate to severe plaque psoriasis. This article summarizes the efficacy and safety of apremilast and provides characterization of the novel medication with clinical perspectives to successfully incorporate this therapy into practice for appropriate patients. DATA SOURCES: A review and synthesis of the results from the ESTEEM (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis) phase 3 clinical studies evaluating the efficacy, safety, and tolerability of apremilast for the treatment of moderate to severe plaque psoriasis was conducted...
December 2016: Journal of the American Association of Nurse Practitioners
https://www.readbyqxmd.com/read/27864841/clinical-factors-predicting-the-therapeutic-response-to-ustekinumab-in-patients-with-moderate-to-severe-chronic-plaque-psoriasis
#14
Young Ji Hwang, Sang Woong Youn, Bo Ri Kim, Dae Young Yu, Youngdoe Kim, Antonio Pires, Soyun Cho, Seong Jun Seo, Eun So Lee, Joo Young Roh, Gwang Seong Choi, Min Geol Lee
While ustekinumab has been widely used as an effective biologic for the treatment of chronic plaque psoriasis, no prospective studies have specifically investigated the clinical factors that may influence treatment outcomes with ustekinumab. This post-hoc analysis aimed to identify specific clinical factors that may influence treatment outcomes with ustekinumab in psoriasis patients. In the MARCOPOLO study, 102 Korean patients with moderate to severe psoriasis were analyzed to assess the influence of baseline characteristics as clinical factors on clinical response (improvement in Psoriasis Area and Severity Index by ≥75%/90% [PASI75/PASI90]) to ustekinumab...
November 18, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27864793/serum-fatty-acid-binding-protein-4-is-increased-in-patients-with-psoriasis
#15
A Baran, M Świderska, Joanna Bacharewicz-Szczerbicka, H Myśliwiec, I Flisiak
Psoriasis is associated with metabolic syndrome and cardiovascular disease. Fatty acid-binding proteins (FABP) have been recognized as predictors of these systemic disorders. The aim of this study was to assess correlations between levels of serum heart and adipocyte fatty acid-binding proteins (FABP3, FABP4) and disease severity, indicators of inflammation or metabolic disturbances, and topical treatment in psoriatic patients. Thirty-seven patients with relapse of plaque-type psoriasis and 16 healthy volunteers were recruited...
November 18, 2016: Lipids
https://www.readbyqxmd.com/read/27859546/first-in-human-randomised-study-of-bimekizumab-a-humanised-monoclonal-antibody-and-selective-dual-inhibitor-of-il-17a-and-il-17%C3%A2-f-in-mild-psoriasis
#16
S Glatt, E Helmer, B Haier, F Strimenopoulou, G Price, P Vajjah, O A Harari, J Lambert, S Shaw
AIMS: Assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab, (formerly UCB4940), a novel humanised monoclonal antibody and dual inhibitor of interleukin (IL)-17A and IL-17 F, in subjects with mild plaque psoriasis. METHODS: Randomised, double-blind, first-in-human study of bimekizumab in 39 subjects who received single-dose intravenous (iv) bimekizumab (8-640 mg) or placebo (NCT02529956). RESULTS: Bimekizumab demonstrated dose-proportional linear PK and was tolerated across the dose range assessed...
November 13, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27845513/the-switching-from-a-biological-therapy-to-another-biologic-agent-in-psoriatic-patients-the-experience-of-psomarche-group
#17
Giulia Ganzetti, Anna Campanati, Alberta Bettacchi, Giuliano Brandozzi, Valerio Brisigotti, Leonardo Bugatti, Ivana Cataldi, Giorgio Filosa, Alfredo Giacchetti, Giuseppe Lemme, Lorenzo Morresi, Massimiliano Nicolini, Valentina Postacchini, Giuseppe Ricotti, Laura Rosa, Marco Simonacci, Annamaria Offidani
BACKGROUND: Switching is a "hot" topic and the main reasons for switching prior biologic agent are for a primary failure, a secondary failure or drug intolerance, patient's dissatisfaction, physician decision. The aim of the study was to assess the optimization of the switching from a biological to another. METHODS: Five Dermatological Units have participated to PsOMarche working group have studied thirty-eight patients affected moderate to severe chronic plaque psoriasis at time 0 (patient recruitment at time of switching from biological therapy to another), 8 weeks (T8), 16 weeks (T16)...
November 15, 2016: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/27828628/c-reactive-protein-serum-level-in-patients-with-psoriasis-before-and-after-treatment-with-narrow-band-ultraviolet-b
#18
Mahmoud Farshchian, Akram Ansar, Mohammadreza Sobhan, Valiollah Hoseinpoor
Background: C-reactive protein is an inflammatory biomarker and its level increases in the serum of psoriatic patients. Its level is also associated with Psoriasis Area and Severity Index score. Objective: The aim of this study was to assess the decrement of serum C-reactive protein level with narrow-band ultraviolet B (NB-UVB) therapy. Methods: C-reactive protein serum levels in psoriasis patients were measured before and after treatment with NB-UVB and the data were analyzed in relation to the Psoriasis Area and Severity Index score improvement...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/27825174/a-review-of-ixekizumab-an-anti-interleukin-17a-monoclonal-antibody-for-moderate-to-severe-plaque-psoriasis
#19
A J Peranteau, A E Turkeltaub, Y Tong, Z Nawas, S K Tyring
Psoriasis is a multifactorial chronic skin disease that can have significant detrimental effects on patients' physical, mental, antibodypsychosocial wellbeing. Patients often suffer from a decreased quality of life along with numerous comorbidities. Recent advances in our understanding of the innate and adaptive immune systems have led to the identification of interleukin (IL)-17 as a key pro-inflammatory mediator in psoriasis. This knowledge has in turn led to the development of newer biologic agents that have been shown to be more effective than traditional therapies...
November 2016: Skin Therapy Letter
https://www.readbyqxmd.com/read/27819714/patient-reported-outcomes-and-clinical-response-in-patients-with-moderate-to-severe-plaque-psoriasis-treated-with-tonsillectomy-a-randomized-controlled-trial
#20
Ragna Hlin Thorleifsdottir, Sigrun Laufey Sigurdardottir, Bardur Sigurgeirsson, Jón Hjaltalin Olafsson, Martin Ingi Sigurdsson, Hannes Petersen, Johann Eli Gudjonsson, Andrew Johnston, Helgi Valdimarsson
Psoriasis is a chronic inflammatory skin disease with profound effects on patients' health-related quality of life (HRQoL). Twenty-nine patients with plaque psoriasis and a history of streptococcal-associated psoriasis exacerbations were randomly assigned to tonsillectomy (n = 15) or control (n = 14) groups and followed for 24 months. Patients were evaluated with the Psoriasis Disability Index, Psoriasis Life Stress Inventory and Psoriasis Area and Severity Index. HRQoL and psoriasis-related stress improved significantly in the tonsillectomy group compared with the control group (p = 0...
November 7, 2016: Acta Dermato-venereologica
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"